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Sleep problems have not been directly reported in phenylketonuria (PKU). In PKU, 
the metabolic pathway of phenylalanine is disrupted, which, among others, causes 
deficits in the neurotransmitters and sleep modulators dopamine, norepinephrine, 
and serotonin. Understanding sleep problems in PKU patients may help explain the 
pathophysiology of brain dysfunction in PKU patients. In this explorative study, we 
investigated possible sleep problems in adult treated PKU patients and untreated PKU 
mice. In the PKU patients, sleep characteristics were compared to healthy first degree 
relatives by assessment of sleep disturbances, sleep–wake patterns, and sleepiness 
with the help of four questionnaires: Holland sleep disorder questionnaire, Pittsburgh 
sleep quality index, Epworth sleepiness scale, and Munich Chronotype Questionnaire. 
The results obtained with the questionnaires show that PKU individuals suffer more 
from sleep disorders, a reduced sleep quality, and an increased latency to fall asleep 
and experience more sleepiness during the day. In the PKU mice, activity patterns 
were recorded with passive infrared recorders. PKU mice switched more often 
between active and non-active behavior and shifted a part of their resting behavior 
into the active period, confirming that sleep quality is affected as a consequence of 
PKU. Together, these results give the first indication that sleep problems are present in 
PKU. More detailed future research will give a better understanding of these problems, 
which could ultimately result in the improvement of treatment strategies by including 
sleep quality as an additional treatment target.
Keywords: inherited metabolic disorder, Pahenu2 mice, phenylketonuria patients, phenylketonuria mice, 
neurotransmitters, sleep disorders
inTrODUcTiOn
In 2014, Gadoth and Oksenberg reviewed the incidence of sleep and sleep disorders in patients 
with inherited metabolic disease (IMD). Although their review focused on sleep-related breathing 
disorders among severely affected subjects with IMD, the general title suggested that sleep problems 
could be missed or underestimated in these conditions. A metabolic disease in which brain modula-
tors of sleep are severely affected but attention for sleep research is very limited is phenylketonuria 
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(PKU). PKU is caused by an inborn error in the metabolic 
pathway of phenylalanine (Phe) that disrupts the conversion of 
Phe to tyrosine. As a result, Phe concentrations build up in blood 
and brain and the ability to intrinsically produce the dopamine 
precursor tyrosine is lost. These changes do not solely affect 
the metabolism of dopamine. Also, reduced concentrations of 
noradrenaline and serotonin are found in PKU patients (1, 2) and 
in the PKU mouse model (3). These neurotransmitters are known 
to be important regulators of sleep, wakefulness, and switches 
between these states (4, 5). Nevertheless, these abnormalities in 
neurotransmitter availability are not specifically linked to pos-
sible sleep problems in PKU research. In PKU research, a few 
studies have indirectly investigated sleep regulators or sleep. First, 
in treated and untreated PKU patients, sleep-EEG measurements 
indicate differences in the number of sleep spindles despite 
similar REM and non-REM distribution compared to healthy 
controls (6). Second, in early-treated PKU infants (4–18 weeks 
old), EEG measurements show differences in the development of 
sleep compared to healthy controls (7). Finally, in the PKU mouse 
model, high levels of orexin A (hypocretin 1) were reported, a 
neuropeptide that is associated with wakefulness (8, 9). This 
made the authors suggest hyperactivity in PKU, however, the 
exact consequence of these increased levels are not clear while 
hyperactivity is not consistently described in PKU mice (10).
Currently, PKU treatment remains suboptimal in which 
disturbances in executive functions, mood, social cognition, 
and in internalizing problems, such as depression and anxiety, 
are described in early-treated PKU patients (11, 12). As it is well 
established that altered sleep negatively influences cognitive per-
formance, most notably in the domains of executive functioning 
(13–15), and mood by impacting feelings of depression, anxiety, 
and stress (16, 17), sleep-related issues could very well serve as 
an explanation of the PKU brain dysfunction despite diet and 
drug treatment.
Understanding the presence and severity of sleep problems 
in PKU patients and its pathophysiology could ultimately result 
in the improvement of treatment strategies by including sleep 
quality as an additional treatment target. Therefore, the aim of 
this explorative study was to investigate the presence of sleep 
disturbances in PKU patients with questionnaires together with 
analyses of rest/wake patterns in PKU mice, indirectly reflecting 
sleep characteristics which could confirm the PKU-specific nature 
of putative sleep issues in PKU patients. As sleep is influenced 
by, among others, genetic factors (18–21), first-degree relatives 
(FDR) of PKU patients and wild-type (WT) littermates of each 




In the summer of 2016, participants for this study were recruited 
by distributing a link to an electronic survey to subjects associ-
ated with the Dutch PKU patient organization. PKU patients and 
FDR, who did not do shift work in the past 3 months, were asked 
to fill out four questionnaires with 10 additional questions (date 
of birth, zip code, gender, height, bodyweight, PKU or control, 
treatment of PKU, other health issues, smoking, and the use of 
sleep-promoting drugs). All participants were informed about 
the scientific purpose of the study and agreed to participate. They 
completed the questionnaires completely anonymous. To ensure 
that the questionnaires were not completed by the same individu-
als more than once, the submissions were checked for uniqueness, 
focusing on date of birth and IP address. In total, 47 subjects, 
25 PKU patients and 23 controls, participated.
Sleep Questionnaires
Four validated questionnaires were included in the survey: (1) 
Holland Sleep Disorders Questionnaire (HSDQ) (22); 40 items, 
(2) Pittsburgh Sleep Quality Index (PSQI) (23); 19 items, (3) 
Epworth Sleepiness Questionnaire (ESS) (24); 8 items, and (4) 
Munich Chronotype Questionnaire (MCTQ) (25); 16 items. 
First, the HSDQ gives a general score to identify the possible 
occurrence of a sleep disorder and can differentiate between six 
main categories of sleep disorders [insomnia, parasomnia, circa-
dian rhythm sleep disorders (CRSD), hypersomnia, sleep-related 
movement disorders, such as for instance restless legs syndrome, 
and sleep-related breathing disorder] (22). Second, for the PSQI, 
seven component scores can be derived (subjective sleep qual-
ity, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbances, use of sleep medication, and daytime dysfunction) 
and computed to a global score (23). Third, the ESS is used to 
examine sleepiness during the day (for instance during reading) 
(24). Finally, the MCTQ was used to identify chronotype (the 
preferred timing of sleep) calculated by taking the mid-point of 
sleep on free days corrected for the sleep debt acquired during 
working days (26).
PKU Mouse study
To investigate the rest/wake pattern in PKU mice, the home-cage 
activity of adult (4–7 months) WT and PKU mice of BTBR and 
C57Bl/6 (B6) background was monitored. Both genetic strains of 
the PKU mouse model have a point mutation in the gene encod-
ing for phenylalanine hydroxylase causing Phe to rise in blood 
and brain (10). The PKU model was originally described for the 
BTBR background but the model was latter crossed back on to 
the C57Bl/6J background. Currently, both genetic strains are used 
in PKU research. In-house heterozygous mating pairs were used 
to breed the following groups of mice: BTBT WT, BTBR PKU, 
B6 WT, and B6 PKU. These mice were weaned on postnatal day 
28, and genotype was established with quantitative PCR (10). The 
experiment consisted of a habituation phase and a data-acquiring 
phase. After a 7-day habituation phase, the activity of individual 
housed mice (cage: 33 cm × 15 cm × 14 cm with nesting material 
and paper role) were monitored for 7 days with passive infrared 
detectors (PIR). During the whole experiment, animals were 
on a 12/12 light/dark cycle and had ad  libitum access to water 
and normal chow (RMH-B 2181, ABdiets, Phe: 8.7 g/kg). Data 
were analyzed with ACTOVIEW [made in-house, described in 
Ref. (27)]. This program calculated the average daily activity, diur-
nality [(Sum activity light phase − sum activity dark phase)/total 
activity], and fragmentation (28) from the files produced by the 
circadian activity monitor system (CAMS) collected from the PIR.
Table 1 | subject characteristics.
hsDQ PsQi ess McTQ
PKU FDr-control PKU FDr-control PKU FDr-control PKU FDr-control
Number 25 21 21 15 22 17 24 17
Age 29.2 ± 8.8 44.2 ± 10.1 30.1 ± 9.0 46.6 ± 10 29.6 ± 9.1 45.9 ± 10.1 29.0 ± 8.9 45.9 ± 10.1
BMI 24.1 ± 4.3 25.0 ± 5.1 24.5 ± 4.3 24.8 ± 5.6 24.6 ± 4.2 24.6 ± 4.2 24.4 ± 4.1 24.6 ± 4.2
Gender (F/M) 17/8 16/5 15/6 11/4 16/6 12/5 16/8 12/5
Smoking 4 1 4 1 4 1 4 1
Heath issues 5 0 4 0 4 0 5 0
Sleep-promoting drugs 5 0 5 0 5 0 5 0
Kuvan® 3 2 2 3
Kuvan® + protein restricted 4 3 3 3
Protein restricted 22 16 17 18
Data are presented as mean ± SD.
F, female; M, male; HSDQ, Holland Sleep Disorders Questionnaire; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Questionnaire; MCTQ, Munich Chronotype 
Questionnaire; PKU, phenylketonuria; FDR-control, first-degree relatives-control.
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statistics
The statistical analysis was executed with the statistical software 
IBM SPSS Statistics for Windows, Version 22.0 (Armonk, NY, 
USA: IBM Corp.). Within this program, the Shapiro–Wilk was 
used to test normality of the data. The activity of the mice was 
normally distributed, and a multi-variate ANOVA was used to 
test the factors group and gender of overall activity, fragmenta-
tion, and diurnality. Differences in group characteristics in the 
patient study were not normally distributed and, therefore, tested 
with the non-parametric Mann–Whitney U test. The chronotype 
score of the MCTQ, normally distributed, was tested with a 
univariate ANOVA for group. Age and gender were included as 
cofactors. The ordinal nature of the HSDQ, PSQI, and ESS scores, 
made it not possible to test confounding factors parametrically. 
Therefore, gender and age were explored with generalized linear 
models, using an ordinal model. Differences in the frequency of 
occurrence of sleep disorders were also tested with a generalized 
linear model, using a binary model. Non-parametric Levene’s test 




This study is a pilot study serving as a proof-of-concept for sleep-
related issues due to PKU. For this reason, individuals were included 
when they correctly filled out at least one of the questionnaires. Not 
all questionnaires were correctly filled out by all subjects, which 
resulted in different group characteristics for each questionnaire 
(Table 1). For all questionnaire responses, the FDR controls were 
significantly older than the PKU subjects [HSDQ: p < 0.05, PSQI: 
p < 0.05, Epworth Sleepiness Questionnaire (ESS): p < 0.05, MCTQ: 
p < 0.05] but no differences were found in BMI (HSDQ: p = 0.68, 
PSQI: p = 0.92, ESS: p = 0.99, MCTQ: p = 0.90). Furthermore, no 
significant differences were found in gender distribution of the 
groups [HSDQ: t(44) = −0.603, p =  0.55, PSQI: t(35) =  0.172, 
p =  0.87, ESS: t(37) =  0.143, p =  0.89, MCTQ: t(39) = −0.260, 
p = 0.80]. One FDR control was excluded because she used several 
sleep-promoting drugs (Trazodon and zolpidem tartrate).
Frequency of Sleep Disorders
The global score of the HSDQ is used to identify the presence of 
a sleep disorder with an overall accuracy of 88% (κ: 0.75) (22). 
In PKU patients, 48% had a global score above the cutoff of 2.02, 
indicative of a sleep disorder, compared to 19% of FDR controls 
[Figure 1A; b = 1.367, Wald χ2(1, N = 46) = 3.983, p < 0.05]. 
Especially, among the six main sleep disorder categories, PKU 
patients had a higher score for both insomnia and CRSD 
[Figure 1B: b = −1.527, Wald χ2(1, N = 46) = 7.626, p < 0.05, 
Figure 1C: b = −1.593, Wald χ2(1, N = 46) = 8.115, p < 0.05, 
respectively], but not for the other four categories [parasomnia; 
b = −0.985, Wald χ2(1, N = 46) = 2.941, p = 0.086, hypersomnia; 
b = −0.985, Wald χ2(1, N = 46) = 3.287, p = 0.070, restless legs 
syndrome; b = −0.696, Wald χ2(1, N = 46) = 1.757, p = 0.185, 
and sleep-related breathing disorder; b  =  −0.693, Wald 
χ2(1, N = 46) = 1.688, p = 0.194]. Age and gender did not signifi-
cantly contribute to these models. These results reveal a higher 
frequency of sleep disorders, more specifically insomnia and 
CRSD, in PKU patients.
Sleep Quality
The global PSQI, comprised seven sleep-related components, is 
used to classify poor (>5) and good sleepers (≤5). This global 
score was significantly higher in the PKU patients of which more 
people were classified as poor sleepers (57%) compared to the 
FDR controls of which 25% were classified as poor sleepers 
[Figure 2A: b = −1.674, Wald χ2(1, N = 37) = 7.102, p < 0.05]. 
Within the global score, two component scores differed between 
PKU patients and FDR controls. The first was the component 
score for latency to fall asleep which was significantly increased in 
PKU patients [FDR: 0.44 ± 0.63, PKU: 1.43 ± 0.98, b = −2.306, 
Wald χ2(1, N = 37) = 9.733, p < 0.05]. The second one was the 
component score for subjective sleep quality. This score was com-
puted from the question in which subjects could indicate their 
quality of sleep during the past month on a scale of very good 
(score 0) to very bad (score 3). This score was significantly higher 
in PKU patients than in the FDR controls [FDR: 0.69 ±  0.60, 
PKU: 1.38 ±  0.92, b = −1.655, Wald χ2(1, N =  37) =  5.516, 
p <  0.05]. Age and gender did not significantly contribute to 
FigUre 1 | holland sleep Disorders Questionnaire (hsDQ). (a) Results 
from the global score of HSDQ indicate that 48% of the phenylketonuria 
(PKU) patients have a sleep disorder compared to 19% of the first-degree 
relatives (FDR) controls. (b) PKU patients have a significant higher insomnia 
score than FDR controls. Six PKU patients are above the cutoff score 
compared to 0 FDR controls. (c) Although only two PKU patients are above 
the cutoff score, PKU patients have significant higher circadian rhythm sleep 
disorders score compared to FDR controls. Data represent individual scores 
with median. Dotted line represents cutoff score between having sleep 
problem or not (**p < 0.01).
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these models. These results suggest that sleep quality is reduced 
in PKU patients compared to FDR controls.
Sleepiness during the Day
In the ESS, the participant subjectively rate the chance of dozing 
off during eight situations from “none” (score 0) to “high” (score 
3). This score is significantly higher in PKU patients than FDR 
controls [Figure 2B; b = −1.608, Wald χ2(1, N =  39) =  6.597, 
p <  0.05]. A main effect of age and gender did not contribute 
significantly to the model. These results suggest that PKU patients 
experience more sleepiness during daytime.
Chronotype
In the MCTQ, the sleep schedules of the participants on working 
and non-working days were asked. From these data, we could 
calculate chronotype, defined as the mid-sleep on free days cor-
rected for the potential sleep debt acquired during the working 
days (26). Chronotype is dependent on age and gender (26), 
therefore, statistical analysis included age and gender as a cofactor. 
No significant differences were found between chronotype scores 
in PKU patients and FDR controls or for any of the cofactors in 
the complete model [group: F(1,37) = 1.287, p = 0.26, gender: 
F(1,37) = 0.954, p = 0.34, age: F(1,37) = 1.941, p = 0.17].
PKU Mice
Rest/Wake Patterns
No main or interaction effects were observed for sex in all param-
eters, therefore, data of males and females were grouped. The frag-
mentation score is indicative of the frequency that active behavior 
is switched to non-active behavior and vice versa. In PKU mice, 
in both strains, the fragmentation score was increased compared 
to WT [Figure 3A; F(3,56) = 10.803, p < 0.05, BTBR p < 0.05, 
p  <  0.05]. Although differences were found in overall activity 
between the WT’s of each strain [BTBR WT: 3,162.46 ± 1,239.24, 
B6 WT: 2,193.69 ± 785.91 (mean ± SD) F(3,56) = 3.858, p < 0.05, 
BTBR WT vs. B6 WT p = 0.019], the increase in fragmentation 
score found in PKU mice did not coincide with a change in overall 
activity (BTBR PKU: 2,655.42 ± 605.23, B6 PKU: 2,306.90 ± 860.06, 
BTBR p = 0.67, B6 p = 1.000). However, a shift did occur in the 
timing of the rest/active behavior. The negative diurnality score, 
reflecting night activity in animals, became less negative in PKU 
mice [Figure 3B; F(3,56) = 8.235, p < 0.001, BTBR p < 0.05, B6 
p < 0.05]. These results reveal that PKU mice have increased frag-
mentation and a shift in diurnality (more inactive in active phase).
DiscUssiOn
In this explorative study, we investigated sleep characteristics in 
PKU patients with questionnaires and analyzed the rest/wake 
patterns in PKU mice. In the PKU patients study, we showed 
that PKU patients compared to FDR controls have more sleep 
disorders, a reduced sleep quality, an increased latency to fall 
asleep, and experience more sleepiness during the day. In the 
PKU mice, we found an increase in fragmentation and a shift in 
diurnality. The increase in fragmentation indicated that the PKU 
mice switch more often between active and non-active behavior. 
This score did not coincide with changes in overall activity. In 
addition, PKU mice shift a part from their resting behavior into 
the active phase (a shift in diurnality). Both experiments strongly 
support the hypothesis that sleep is affected in PKU. This seems 
to be directly related to the disorders as the deficits were found 
in both PKU mouse strains despite their genetic differences and 
cognitive sensitivity to the PKU condition (10).
study limitations
Sleep is influenced by, among others, genetic factors, age, and 
gender (18–21). For this reason, this study recruited FDR of PKU 
patients as control group. No differences were found in gender 
FigUre 2 | Pittsburgh sleep Quality index (PsQi) and ess. (a) The global score of the PSQI was significantly higher in phenylketonuria (PKU) patients 
compared to first-degree relatives (FDR) control. The dotted line represents the cutoff between good and poor sleepers. Fifty-seven percent of the PKU patients  
are above this cutoff and categorized as poor sleepers. (b) Epworth Sleepiness Questionnaire (ESS) patients experience more sleepiness during the day than FDR 
controls. Data represent individual scores with median (*p < 0.05, **p < 0.01).
FigUre 3 | characteristics of the rest/wake pattern in mice. (a) In both genetic strains of the phenylketonuria (PKU) mouse model, an increase in 
fragmentation is seen in the PKU mice compared to WT littermates. Furthermore, a significant difference is found between the fragmentation score of PKU mice of 
each strain. (b) In the graph, negative diurnality scores are observed. This indicates that we are investigating animals which are active in the dark. PKU mice have a 
less distinct negative score suggesting that they shift part of their resting behavior into the light phase. Data are depicted as mean ± SEM (*p < 0.05, **p < 0.01).
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distributions between the groups, but differences were found in 
age between FDR controls and PKU patients. Although we rec-
ognize these limitations, we believe that it does not hamper our 
results obtained in the first three questionnaires (HSDQ, PSQI, 
ESS) for the following reason. Literature shows either no effect or 
a deterioration of sleep with aging. For example, the PSQI is not 
affected by age (29). The ESS score is influenced by an age × gender 
interaction, wherein females tend to have higher scores between 0 
and 39 age group compared to males (30). Around the ages 40–49, 
the ESS score of males deteriorates reaching the same ESS score 
as females. Therefore, the ESS score is either higher or stays con-
stant with increasing age (30). This implies that the higher scores 
found in the younger PKU patients compared to the older FDR 
controls are contrary to what would be expected and likely reflect 
a real indication of sleep problems in PKU patients. Moreover, no 
significant effect of age was found in our study.
sleep characteristics are altered in PKU
The different measurements of sleep used in this study reveal a 
variety of sleep problems and show some specifically affected 
characteristics of sleep. In the HSDQ, PKU patients show a higher 
incidence in sleep disorders, but only in the main categories 
insomnia and CRSD scores were higher in PKU patients than in 
FDR controls. CRSD were changed to circadian rhythm sleep–
wake disorders (CRSWD) in the third edition of the International 
classification of sleep disorders (31). CRSWD are sleep disorders 
grouped under dyssomnias, a group of sleep disorders, which 
show insomnia, excessive sleepiness, or difficulty initiating or 
maintaining sleep (31). In the current study, we found an increased 
score for insomnia and an increased sleepiness during the day in 
the ESS in PKU patients, supporting the idea that PKU patients 
experience problems specific for this cluster of sleep disorders. 
CRSWD are disorders related to the timing of sleep (31). Some 
are a consequence of external circumstances, e.g., shift work or jet 
lag, others have potentially a more internal, neurological basis, e.g., 
delayed sleep phase syndrome (DSPS). In DSPS, the latency to fall 
asleep opposed to the desired time to fall asleep is delayed. DSPS 
patients experience difficulties to shift their sleep/wake pattern 
to an earlier time point in response to environmental time cues, 
for example traveling from Europe to Asia, and do not experience 
sleepiness when they are able to sleep at their desired time, as is 
possible for instance during a holiday or vacation period. In this 
6Bruinenberg et al. Sleep Disturbances in PKU
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study, we showed that PKU patients report an increased latency 
to fall asleep in the PSQI. However, we did not see a difference 
in the mid-sleep on non-working days when age was a cofactor. 
This could be because mid-sleep is strongly influenced by age and 
the age was not distributed evenly over the full width of both 
groups (26). Therefore, an important future direction is to com-
pare age-matched controls to PKU patients. Further research in 
PKU should focus on (1) more objective measurements of sleep, 
such as polysomnography or sleep–wake rhythm analysis with 
(2) phase shift experiments in PKU mice to identify problems 
in shifting sleep/wake patterns (and neurological substrates), (3) 
monitoring sleepiness during the day specifically during holidays 
and (4) core body temperature and dim-light melatonin rhythm 
monitoring to investigate if PKU patients experience a blunted or 
delayed internal rhythm of physiological markers.
The switch between sleep and 
Wakefulness is Defective in PKU
The HSDQ identifies sleep disorders and attribute certain scores 
to six symptom clusters. These clusters may be due to differ-
ent sleep disorders, possibly with different pathophysiological 
mechanism. For instance, the comorbidity of insomnia with 
other sleep disorders is very high (22). The PKU mouse study 
did identify a more specific aspect of sleep, namely increased 
fragmentation. In general, an increased fragmentation score 
indicates an increase in switching behavior. Switching between 
sleep and wakefulness is thought to be regulated by a flip-flop 
switch that results from mutual inhibition of sleep-promoting 
pathways and wake-promoting pathways (32). Several cholin-
ergic and monoaminergic projections are important in these 
pathways, such as serotonin, norepinephrine, and dopamine 
(32). As these latter neurotransmitters are affected in PKU mice 
(and in untreated PKU patients), it could be that the increased 
fragmentation score is a consequence of disruptions in this 
switch. In early-treated patients on diet, neurotransmitter defi-
ciencies in dopamine and serotonin are still present (2). These 
deficiencies could possibly affect the switch between sleep and 
wakefulness and cause fragmentation of the sleep/wake rhythm 
in PKU patients, more difficulty falling asleep and as a conse-
quence daytime sleepiness.
conclusion
This explorative study is the first to investigate sleep disturbances 
both in PKU patients and PKU mice. In PKU patients, we demon-
strate more sleep disorders, a reduced sleep quality, an increased 
latency to fall asleep, and more sleepiness during the day. We 
show in PKU mice an increased fragmentation and a shift in 
diurnality. These results produce the first evidence to suggest that 
sleep problems occur in PKU. The resulting complaints associ-
ated with altered sleep are comparable to the cognitive symptoms 
described for early and continuously treated PKU patients. More 
detailed future research will give a better understanding and 
further identify sleep problems in PKU, which could ultimately 
result in the improvement of treatment strategies by including 
sleep quality as an additional treatment target.
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